Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

NCT07758231 · Not yet recruiting

Last updated 2026-08-27

This clinical trial tests how a GLP-1 receptor agonist affects alcohol levels in the blood of adults who consume alcohol.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 5 people Planned (estimated).

Who can join Ages 21–55 · all sexes Healthy volunteers accepted.

Timeline Started 2026-10 · est. completion 2027-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07758231 ↗

Description as written by the study sponsor.

This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.

Treatments tested

Acute Ethanol Dose also known as vodka Drug

Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g/dL using the Widmark formula. A total time of 30 minutes will be given for completion of beverage consumption. This will be followed by a breakfast.

Main thing measured	Maximum Ethanol Concentration (Cmax)
Sponsor	University of Wisconsin, Madison
Conditions studied	GLP-1, Alcohol
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07758231 ↗